Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registryopen access
- Authors
- Lee, Jun Young; Kim, Sung Hwa; Park, Yeon Ho; Park, Jae Berm; Lee, Su Hyung; Yang, Jaeseok; Kim, Myoung Soo; Kim, Deok Gie
- Issue Date
- Sep-2022
- Publisher
- The Korean Society of Nephrology
- Keywords
- Aged; Diabetes mellitus; Immunosuppressive agents; Kidney transplantation; Transplantation immunology
- Citation
- Kidney Research and Clinical Practice, v.41, no.5, pp.623 - 634
- Journal Title
- Kidney Research and Clinical Practice
- Volume
- 41
- Number
- 5
- Start Page
- 623
- End Page
- 634
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85944
- DOI
- 10.23876/j.krcp.21.310
- ISSN
- 2211-9132
- Abstract
- Background: Basiliximab (BSX) and antithymocyte globulins (ATGs), are two major immunosuppressive agents commonly used as induction therapy for kidney transplant (KT) recipients. The superiority of ATG over BSX has not been well established, especially in elderly KT recipients with low immunological risk. Methods: A total of 847 elderly (≥60 years old), low-risk KT patients in the Korean Organ Transplantation Registry were propensity score-matched at a 1:2 ratio and compared according to ATG or BSX induction therapy. The primary outcome was patient and graft survival and biopsy-proven acute cellular rejection. The secondary outcome was graft function, BK virus nephropathy, infection, cancer, new-onset diabetes mellitus after transplantation (NODAT), and delayed graft function. Results: In total, 165 patients in the ATG group were matched with 298 patients in the BSX group with average ages of 64.3 and 64.2 years, respectively. During a follow-up of 28.5 ± 10.4 months, the cumulative probabilities of death-censored graft failure at 3 years posttransplantation were 1.3% and 1.4% in ATG and BSX groups, respectively, without a significant difference (p = 0.72). The cumulative probability of NODAT at 3 years posttransplantation was significantly higher in the BSX group (35.6% vs. 21.6%, p = 0.02). The median tacrolimus trough level was significantly lower at 6 months after KT in the ATG group (5.7 ng/mL vs. 6.4 ng/mL, p = 0.001). There were no differences in the other evaluated outcomes. Conclusion: Compared with BSX, in elderly, low-risk KT patients, ATG reduced tacrolimus and steroid requirements without differences in all-cause mortality, rejection, or infection, resulting in a reduced NODAT incidence. © 2022 by The Korean Society of Nephrology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85944)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.